Oliver Ahnfeld is a co-founder of PROVIREX. He has been one of the CEOs of the company since its inception in 2019, and has focused on its entrepreneurial transformation into a biotech company. He has been part of the team for more than 8 years and is responsible for the financial/contractual aspects and the strategic direction of PROVIREX. He studied industrial engineering in Hamburg and has several years of experience in preparing business and financial plans as well as accompanying private placements.

Dr. Jan Chemnitz is a co-founder of PROVIREX. Since its inception, he has been one of the company’s CEOs and has focused on its transition from start-up to a Series A funded biotech company. He is also responsible for building up a collaborative network with other biotech companies as well as academia and implementing the ongoing academic clinical study “HIVCure” into the company’s future strategy.

He studied biochemistry/molecular biology in Jena. After his PhD at the Leibniz Institute of Virology in Hamburg, he joined the Hauber group as a postdoc and was involved in the development of the recombinase technology from the beginning; he has now been working in the field of HIV cure strategies for 20 years.

Dr. Niklas Beschorner is a co-founder of PROVIREX. He participates in the active management of the company and focuses on process development, preclinical research and development work. He is also involved in the technical equipment of the new laboratories and clean rooms and responsible for the development of novel clinical delivery options for the recombinase technology. He studied biotechnology in Emden.

After his diploma degree in the iso-certified industry in the field of cell line development, he joined the Hauber group at the Leibniz Institute of Virology in Hamburg and became involved with the topic of delivery options for recombinase technology early on, which was also the topic of his PhD. He has now been in the field of HIV cure strategies for over 15 years.

Dr. Maike Voges is a co-founder of PROVIREX. She participates in the active management of the company and, together with experts, leads the introduction of a quality management system, supervises the construction and installation of new laboratories and clean rooms, and implements the quality standards at PROVIREX.

She studied biology in Tübingen, focusing on microbiology, virology and immunology, which she intensified during her PhD at the University of Constance and subsequently at the Leibniz Institute of Virology in Hamburg in the group of Prof. Dr. Joachim Hauber. In between, she worked in the quality control department of a smaller pharmaceutical company and later successfully completed additional training as a clinical monitor. She has been part of the team for more than 10 years.

Dr. Jan Claas has more than 25 years of experience in Biotech & Pharma industry covering a broad spectrum from Pre-clinical Research to Head of International Marketing and General Management. He was responsible for the commercial development and successful launch of innovations on a national & international level and for the leadership of complex organizations with proven success. His international experience is based on 10 years in European Managing Director roles and the collaboration with global players over many years. In addition, he supported Start-up businesses in mentoring and coaching roles in recent years. Dr. Jan-Uwe Claas is joining PROVIREX from March 1st onwards our new Chief Executive Officer and as Partner of PROVIREX.